Skip to search.
 FTSE 100 Down 1.50%

More On IDIX

Quotes

Derivatives

  • Warrants
  • Investment Products

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

  • Income Statement
  • Balance Sheet
  • Cash Flow

(IDIX)

-NasdaqGS
0.00 0.00(0.00%) N/A
Add to Portfolio
Prev Close:N/A
Open:N/A
Bid:N/A
Ask:N/A
1y Target Est:21.50
Beta:0.82
Next Earnings Date:N/A
Day's Range:N/A - N/A
52wk Range:4.83 - 24.50
Volume:0
Avg Vol (3m):N/A
Market Cap:N/A
P/E (ttm):N/A
EPS (ttm):-0.92
Div & Yield:N/A (N/A)
Trade Now
Quotes delayed, except where indicated otherwise. Currency in .

Comparison

Symbol% ChgMkt Cap
IDIX 0.00%N/A
BMYUp 0.86%110.92b
GILDUp 1.41%172.06b
VRTXUp 1.19%30.10b

Key Statistics

Forward P/E (1 yr):N/A
P/S (ttm):N/A
Ex-Dividend Date:N/A

Analysts

Annual EPS Est (Dec-14) :N/A
Quarterly EPS Est (Sep-14) :N/A
Mean Recommendation*:2.4
PEG Ratio (5 yr expected):N/A

* (Strong Buy) 1.0 - 5.0 (Sell)

Analyst Opinion | Estimates

Business Summary

Idenix Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of human viral diseases in the United States and France. more
Your browser doesn't support canvas
SETTINGS
Scrolling
Speed
Display
Price
Submit Feedback